Stay updated on JCAR014 and Durvalumab in Lymphoma Clinical Trial

Sign up to get notified when there's something new on the JCAR014 and Durvalumab in Lymphoma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the JCAR014 and Durvalumab in Lymphoma Clinical Trial page

  1. Check
    6 days ago
    Change Detected
    Summary
    The clinical trial record for JCAR014 and durvalumab is now displayed, with study details, eligibility criteria, outcome measures, and results information. The record states that the trial was terminated due to slow accrual and is no longer recruiting.
    Difference
    100%
    Check dated 2026-11-07T11:44:03.000Z thumbnail image
  2. Check
    13 days ago
    Change Detected
    Summary
    The footer revision changes from v3.7.2 to v3.8.0 while the page continues to display a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-10-31T12:13:46.000Z thumbnail image
  3. Check
    20 days ago
    Change Detected
    Summary
    A site-wide NIH notice announces that agencies are using “Super Intelligence” in place of “Artificial Intelligence” during a transition and links to updates and FAQs.
    Difference
    1%
    Check dated 2026-10-24T11:58:44.000Z thumbnail image
  4. Check
    27 days ago
    Change Detected
    Summary
    The footer revision label changes from v3.7.1 to v3.7.2.
    Difference
    0.2%
    Check dated 2026-10-17T13:34:54.000Z thumbnail image
  5. Check
    34 days ago
    Change Detected
    Summary
    The footer revision label changed from v3.7.0 to v3.7.1 on the 403 error page.
    Difference
    0.2%
    Check dated 2026-10-10T14:38:52.000Z thumbnail image
  6. Check
    41 days ago
    Change Detected
    Summary
    The study record view displays a 403 Forbidden message instead of trial details, with a link back to Home.
    Difference
    0.5%
    Check dated 2026-10-03T14:29:46.000Z thumbnail image

Stay in the know with updates to JCAR014 and Durvalumab in Lymphoma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the JCAR014 and Durvalumab in Lymphoma Clinical Trial page.